search
Back to results

An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation (ADVENT)

Primary Purpose

Parkinson Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
adaptive DBS delivered through AlphaDBS IPG System
conventional DBS delivered through AlphaDBS IPG System
Sponsored by
Newronika
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring Deep Brain Stimulation

Eligibility Criteria

55 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient is ≥55 years old
  2. Patient has been diagnosed with levodopa-responsive idiopathic Parkinson's disease for ≥5 years
  3. The disease stage is II, III or IV according to the Hoehn and Yahr scale
  4. Patient has history of improvement of Parkinson's symptoms as a direct result of administering levodopa
  5. PD-related symptoms are not adequately controlled with medication, including motor complications of recent onset (>4 months duration)
  6. Patient experiences persistent disabling PD-related symptoms or drug side effects (e.g., dyskinesia, motor fluctuations, or disabling "off periods") despite optimal medical therapy
  7. Patient has been selected for bilateral STN or Gpi DBS, independently from this study, in accordance with local standard of care DBS screening
  8. Patient has been selected to receive Medtronic leads model 3389 or 37086, independently from this study, in accordance with local standard of care DBS screening
  9. Patient has DBS circuit integrity assessed and confirmed by impedance testing, before IPG implantation
  10. ≥6 hours per day (waking hours) with poor motor symptoms control (time "OFF" plus time "ON" with dyskinesia) despite optimal medical therapy, as assessed by the 3-day diary
  11. Montreal Cognitive Assessment (MoCA) >26 in MedON condition
  12. Beck Depression Inventory II (BDI-II) score <17 in MedON condition
  13. UPDRS-III improvement by ≥33% following intake of anti-parkinsonian medications
  14. Patient is able to understand the study requirements and the treatment procedures and has provided written informed consent to participate
  15. Patient is willing and capable of completing a 3-day diary and reaches a sufficient level of agreement (> 75%) with study personnel responses
  16. Patient has a responsible caregiver who will help completing the 3-day diary, provide feedback on activities of daily living (ADL), and ensure the patient complies with visit schedule
  17. Patient is willing to maintain a constant anti-PD medication treatment (best medical management) for at least one month prior to study enrollment
  18. Patient is willing and able to attend all study-required visits, complete the study procedures and attend appropriate follow up visits

Exclusion Criteria:

  1. Patient has contraindications for DBS surgery, including any intracranial abnormality (e.g., generalized atrophy, vascular malformation, hydrocephalus, hematoma, cavernous or venous angioma, tumor or metastases, midline shift, etc.) or metallic implant (e.g., aneurysm clip, cochlear implant, etc.)
  2. Patient has a history of suicide attempt or current active suicidal ideation as determined by a positive response to Item 2-5 of suicide ideation sub-scale of the Columbia Suicide Severity Rating Scale (CSSR-S)
  3. Patient has dementia, major depression, seizures, congestive heart failure, uncontrolled diabetes, dialysis, substance use disorders as described in DSM-V, or any other severe medical condition
  4. Patient has any medical condition that could interfere with study procedures, confound the assessment of study endpoints, or prevent a proper data collection
  5. Patient had confirmation of diagnosis of a terminal illness associated with survival <12 months
  6. Patient needs repeated MRI scans
  7. Patient requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)
  8. Patient carries an electrical or electromagnetic implant (e.g., cochlear prosthesis, pacemaker, neurostimulator, etc.)
  9. Patient has, or plans to obtain, an implanted electrical stimulation medical device and/or an implanted medication pump (e.g., DUOPATM infusion pump) and/or is treated with a portable infusion pump
  10. Patient is on anticoagulant therapy which cannot be paused for >5 days before IPG implant surgery
  11. Patient with a history of cranial surgery including ablation procedure or any other previous neurosurgical procedure for the treatment of PD symptoms on either side of the brain
  12. Patient is currently participating in another clinical study (excluding any sub-study of the present study)
  13. Patient is a female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Phase 1a - conventional stimulation

    Phase 1b - adaptive stimulation

    Arm Description

    Stimulation will be delivered bilaterally to the STN or the GPi. The stimulation parameters will be based upon standard practice by the neurologist.

    Stimulation will be delivered bilaterally to the STN or the GPi, with the neurologist-set therapeutic window (which corresponds to the upper and lower limits for aDBS amplitude). The stimulation will be automatically adapted according to the personalized algorithm based on real time LFP analysis.

    Outcomes

    Primary Outcome Measures

    To assess Treatment-Emergent Adverse Events
    To identify Treatment-Emergent Adverse Events (TEAEs) (including serious, device-related, stimulation-related, and/or procedure related TEAEs), discontinuations of aDBS and study discontinuation and physical or neurological findings as categorized by the Data and Safety Monitoring Board.
    To compare change in Good on time (GOT) when the patient receives aDBS versus change in GOT when the patient receives cDBS.
    The expected treatment effectiveness of AlphaDBS IPG System with aDBS mode (∆GOTaDBS = GOTaDBS@3-Months - GOT@Baseline) and with cDBS mode (∆GOTcDBS = GOTcDBS@3-Months - GOT@Baseline) will not differ more than two hours.

    Secondary Outcome Measures

    Success rate, number of patients with at least 2 hours improvement in each treatment mode
    Treatement success is defined as number of patients with >2 hours ∆GOTaDBS and ∆GOTcDBS
    Patient fluctuations
    Number of ON/OFF transitions based on the 3-day diary
    UPDRS III
    UPDRS III score, in MedOFF-StimON and MedON-StimON conditions
    UdysRS
    Score of the Unified Dyskinesia Rating Scale (UdysRS) in MedOFF-StimON and MedON-StimON condition.
    Percentage of time in which the system is used in aDBS mode
    During the long term follow up, when the patient will be able to switch between programming modes, the patient preference will be assessed considering the percentage of time in which the system is used in aDBS.

    Full Information

    First Posted
    February 21, 2022
    Last Updated
    March 2, 2022
    Sponsor
    Newronika
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05262348
    Brief Title
    An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation
    Acronym
    ADVENT
    Official Title
    A Prospective, Multi-center, Open-label, Pivotal Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Stimulation in Advanced Levodopa-Responsive Parkinson's Disease Treated With Bilateral Deep Brain Stimulation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    August 2022 (Anticipated)
    Primary Completion Date
    August 30, 2024 (Anticipated)
    Study Completion Date
    December 31, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Newronika

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No

    5. Study Description

    Brief Summary
    The clinical trial aims to evaluate the safety and effectiveness of bilateral subthalamic nucleus (STN) and Globus Pallidus internus (GPi) deep brain stimulation (DBS) with the AlphaDBS IPG System when programmed in adaptive versus conventional stimulating modes. It includes an initial open-label, crossover phase and a long term follow-up phase, during which the patient is free to switch between stimulating modes.
    Detailed Description
    This is an international multi-center (North America and Europe) clinical trial to evaluate the safety and effectiveness of bilateral STN and GPi DBS with the AlphaDBS IPG System when programmed in adaptive (aDBS) versus conventional (cDBS) stimulating modes, in patients with advanced levodopa-responsive Parkinson's disease (PD). The protocol is comprised of: Phase 1: Initial Treatment Period: Cross-Over Design Phase 1a: All patients will start the study in cDBS mode. After a 1-month post-surgical stabilization, the AlphaDBS IPG System will be turned ON in cDBS mode. Participants will complete a 1-month period of programming optimization (to fine tune medical therapies and stimulation parameters) followed by a 3-month period of cDBS. Phase 1b: At the end of the 3-month follow up in cDBS, participants will be switched to the aDBS mode. Participants will then complete a 1-month period of optimization (to fine tune medical therapies and stimulation parameters) followed by a 3-month period of aDBS. Phase 2: Long-term follow-up: Naturalistic Follow-up Design Patients completing Phase 1 are eligible to enter long-term follow-up for up to an additional 28 months. During this time, patients are free to change the DBS mode as preferred (with a maximum switches set by the physician). Visits at 6-month follow-ups will collect safety and efficacy data.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Parkinson Disease
    Keywords
    Deep Brain Stimulation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    51 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Phase 1a - conventional stimulation
    Arm Type
    Active Comparator
    Arm Description
    Stimulation will be delivered bilaterally to the STN or the GPi. The stimulation parameters will be based upon standard practice by the neurologist.
    Arm Title
    Phase 1b - adaptive stimulation
    Arm Type
    Experimental
    Arm Description
    Stimulation will be delivered bilaterally to the STN or the GPi, with the neurologist-set therapeutic window (which corresponds to the upper and lower limits for aDBS amplitude). The stimulation will be automatically adapted according to the personalized algorithm based on real time LFP analysis.
    Intervention Type
    Device
    Intervention Name(s)
    adaptive DBS delivered through AlphaDBS IPG System
    Other Intervention Name(s)
    aDBS
    Intervention Description
    The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive "real-time" fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable.
    Intervention Type
    Device
    Intervention Name(s)
    conventional DBS delivered through AlphaDBS IPG System
    Other Intervention Name(s)
    cDBS
    Intervention Description
    The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
    Primary Outcome Measure Information:
    Title
    To assess Treatment-Emergent Adverse Events
    Description
    To identify Treatment-Emergent Adverse Events (TEAEs) (including serious, device-related, stimulation-related, and/or procedure related TEAEs), discontinuations of aDBS and study discontinuation and physical or neurological findings as categorized by the Data and Safety Monitoring Board.
    Time Frame
    9 months
    Title
    To compare change in Good on time (GOT) when the patient receives aDBS versus change in GOT when the patient receives cDBS.
    Description
    The expected treatment effectiveness of AlphaDBS IPG System with aDBS mode (∆GOTaDBS = GOTaDBS@3-Months - GOT@Baseline) and with cDBS mode (∆GOTcDBS = GOTcDBS@3-Months - GOT@Baseline) will not differ more than two hours.
    Time Frame
    9 months
    Secondary Outcome Measure Information:
    Title
    Success rate, number of patients with at least 2 hours improvement in each treatment mode
    Description
    Treatement success is defined as number of patients with >2 hours ∆GOTaDBS and ∆GOTcDBS
    Time Frame
    9 months
    Title
    Patient fluctuations
    Description
    Number of ON/OFF transitions based on the 3-day diary
    Time Frame
    9 months and 36 months
    Title
    UPDRS III
    Description
    UPDRS III score, in MedOFF-StimON and MedON-StimON conditions
    Time Frame
    9 months and 36 months
    Title
    UdysRS
    Description
    Score of the Unified Dyskinesia Rating Scale (UdysRS) in MedOFF-StimON and MedON-StimON condition.
    Time Frame
    9 months and 36 months
    Title
    Percentage of time in which the system is used in aDBS mode
    Description
    During the long term follow up, when the patient will be able to switch between programming modes, the patient preference will be assessed considering the percentage of time in which the system is used in aDBS.
    Time Frame
    28 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    55 Years
    Maximum Age & Unit of Time
    95 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patient is ≥55 years old Patient has been diagnosed with levodopa-responsive idiopathic Parkinson's disease for ≥5 years The disease stage is II, III or IV according to the Hoehn and Yahr scale Patient has history of improvement of Parkinson's symptoms as a direct result of administering levodopa PD-related symptoms are not adequately controlled with medication, including motor complications of recent onset (>4 months duration) Patient experiences persistent disabling PD-related symptoms or drug side effects (e.g., dyskinesia, motor fluctuations, or disabling "off periods") despite optimal medical therapy Patient has been selected for bilateral STN or Gpi DBS, independently from this study, in accordance with local standard of care DBS screening Patient has been selected to receive Medtronic leads model 3389 or 37086, independently from this study, in accordance with local standard of care DBS screening Patient has DBS circuit integrity assessed and confirmed by impedance testing, before IPG implantation ≥6 hours per day (waking hours) with poor motor symptoms control (time "OFF" plus time "ON" with dyskinesia) despite optimal medical therapy, as assessed by the 3-day diary Montreal Cognitive Assessment (MoCA) >26 in MedON condition Beck Depression Inventory II (BDI-II) score <17 in MedON condition UPDRS-III improvement by ≥33% following intake of anti-parkinsonian medications Patient is able to understand the study requirements and the treatment procedures and has provided written informed consent to participate Patient is willing and capable of completing a 3-day diary and reaches a sufficient level of agreement (> 75%) with study personnel responses Patient has a responsible caregiver who will help completing the 3-day diary, provide feedback on activities of daily living (ADL), and ensure the patient complies with visit schedule Patient is willing to maintain a constant anti-PD medication treatment (best medical management) for at least one month prior to study enrollment Patient is willing and able to attend all study-required visits, complete the study procedures and attend appropriate follow up visits Exclusion Criteria: Patient has contraindications for DBS surgery, including any intracranial abnormality (e.g., generalized atrophy, vascular malformation, hydrocephalus, hematoma, cavernous or venous angioma, tumor or metastases, midline shift, etc.) or metallic implant (e.g., aneurysm clip, cochlear implant, etc.) Patient has a history of suicide attempt or current active suicidal ideation as determined by a positive response to Item 2-5 of suicide ideation sub-scale of the Columbia Suicide Severity Rating Scale (CSSR-S) Patient has dementia, major depression, seizures, congestive heart failure, uncontrolled diabetes, dialysis, substance use disorders as described in DSM-V, or any other severe medical condition Patient has any medical condition that could interfere with study procedures, confound the assessment of study endpoints, or prevent a proper data collection Patient had confirmation of diagnosis of a terminal illness associated with survival <12 months Patient needs repeated MRI scans Patient requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) Patient carries an electrical or electromagnetic implant (e.g., cochlear prosthesis, pacemaker, neurostimulator, etc.) Patient has, or plans to obtain, an implanted electrical stimulation medical device and/or an implanted medication pump (e.g., DUOPATM infusion pump) and/or is treated with a portable infusion pump Patient is on anticoagulant therapy which cannot be paused for >5 days before IPG implant surgery Patient with a history of cranial surgery including ablation procedure or any other previous neurosurgical procedure for the treatment of PD symptoms on either side of the brain Patient is currently participating in another clinical study (excluding any sub-study of the present study) Patient is a female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jason Jones
    Phone
    901-451-4792
    Email
    jason.jones@newronika.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Costanza Conti, PhD
    Phone
    +393405314424
    Email
    costanza.conti@newronika.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation

    We'll reach out to this number within 24 hrs